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httpAssessing the impact of distal protection ﬁlter
design characteristics on 30-day outcomes of
carotid artery stenting procedures
Natasha A. Loghmanpour, MS,a Gail M. Siewiorek, PhD,b Kelly M. Wanamaker, MD,c
Satish C. Muluk, MD,c Rabih Chaer, MD,d Mark H. Wholey, MD,e and Ender A. Finol, PhD,f
Pittsburgh, Pa; and San Antonio, Tex
Objective: This study aims to review retrospectively the records of patients treated with carotid artery stenting (CAS) to
investigate the potential correlations between clinical variables, distal protection ﬁlter (DPF) type and characteristics, and
30-day peri-/postprocedural outcomes.
Methods: This is a multicenter, single-arm, nonrandomized retrospective study of patients who underwent ﬁlter-protected
CAS in the Pittsburgh, Pennsylvania, region between July 2000 and May 2011. Analysis of peri-/postprocedural compli-
cations included myocardial infarction, transient ischemic attacks (TIA), stroke, death, and a composition of all adverse
events (AEs). Filter characteristics forAccunet (AbbottVascular, SantaClara,Calif; n[429 [58.8%]), Angioguard (Cordis
Endovascular, Miami Lakes, Fla; n[ 114 [15.6%]), FilterWire (Boston Scientiﬁc, Natick,Mass; n[ 113 [15.5%]), Spider
(ev3 Endovascular, Plymouth, Minn; n[ 45 [6.2%]), and Emboshield (Abbott Vascular; n[ 24 [3.3%]) were previously
determined in vitro and were used to ﬁnd correlations with CAS procedural outcomes. Both univariate and multivariate
analyses were performed, as well as goodness-of-ﬁt tests to ﬁnd multivariate correlations with procedural outcomes.
Results: In total, 731 CAS procedures using six different DPFs were analyzed. Peri-/postprocedural AEs included 19 TIAs
(2.6%), 38 strokes (5.2%), onemyocardial infarction (0.1%), 19 deaths (3.6%), and a total of 61 patients with complications
(8.3%). Univariate analysis for ﬁlter design characteristics showed that the composite of AE was negatively associated
with both vascular resistance (P[ .01) and eccentricity (P[ .02) and was positively associated with porosity (P[ .0007),
number of pores (P [ .005), and pore density (P [ .001). Multivariate analysis and the goodness-of-ﬁt test revealed
that patients with a history of congestive heart failure, stroke, and TIA (each with odds ratio >1) led to a good-ﬁt model
P value of .72 for peri-/postprocedural AEs. Multivariate analysis was inconclusive for all ﬁlter design characteristics.
Conclusions: The following ﬁlter design characteristics are independently signiﬁcant for minimizing peri-/postprocedural
AEs: higher vascular resistance, concentric in shape, greater capture efﬁciency, lower porosity, lower number of pores, and
lower pore density. Lower porosity and smaller wall apposition were also found to be independently signiﬁcant for
minimization of peri-/postprocedural TIAs. This information can be used when considering the desirable design char-
acteristics of future DPFs.) (J Vasc Surg 2013;57:309-17.)2Stroke is the third leading cause of death in the United
States after heart disease and cancer,1 and it is the leading
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://dx.doi.org/10.1016/j.jvs.2012.08.113Americans. Approximately onemillion stroke-related events
each year are composed of 600,000 new strokes, 180,000
recurrent strokes, and 240,000 transient ischemic attack
(TIA).1 Nearly one third of all strokes are due to atheroscle-
rosis. Carotid endarterectomy (CEA) has been available since
the 1950s and is the current gold standard treatment3-6 for
prevention of stroke, depending on the severity of the carotid
stenosis.7 For high surgical risk patients, CEAmay not be the
best treatment option. Carotid artery stenting (CAS) is
a more recently implemented treatment that now serves as
an alternative to CEA for asymptomatic high-risk patients8
as well as other patient subsets as described by Ricotta et al.9
Although CAS has gained much attention, few studies
have been conducted that incorporate ﬁlter use and type or
consider design characteristics in the analysis of CAS
patient outcome.10-14 Previous studies conducted by our
laboratory15-19 tested these characteristics with an in vitro
bench-top testing apparatus (Fig) and studied their effects
on ﬁlter capture efﬁciency and ﬂow resistance.16 The charac-
teristics included capture efﬁciency, vascular resistance, wall
apposition, porosity, pore density, and eccentricity.
The purpose of this study was to conduct a retrospec-
tive review of CAS patients with the intent of ﬁnding309
Fig. Schematic diagram of the experimental ﬂow apparatus with a carotid ﬂow model.16 CCA, Common carotid artery;
ECA, external carotid artery; ICA, internal carotid artery.
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and design characteristics, and peri-/postprocedural 30-
day outcomes. This study provides a unique look at associ-
ating ﬁlter type as well as ﬁlter design characteristics with
CAS procedural outcome.
METHODS
Subject population and data collection. In thismulti-
center, single-arm, nonrandomized study, the records of
patients who underwent CAS at both the University of Pitts-
burgh Medical Center (UPMC) and West Penn Allegheny
Health System (WPAHS) were retrospectively reviewed
between July 2000 andMay 2011. Data were collected from
two UPMC sites: Shadyside Hospital and Presbyterian Hos-
pital. At each of the two institutes, an Institutional Review
Board protocol was approved under the Health Insurance
Portability and Accountability Act authorization. The inclu-
sion criteria were based on patients who underwent protected
CAS with a distal protection ﬁlter (DPF) and had a complete
registeredmedical history anddocumented30-day follow-up.
The primary exclusion criteria for this study were the
unavailability of detailed documentation on 30-day outcome
of the CAS procedures. Table I provides the complete list of
baseline characteristics collected for each patient record.
The procedures were carried out by several physicians
in the vascular surgery and cardiology departments at
both UPMC and WPAHS. Patients were considered symp-
tomatic if they had experienced amaurosis fugax, TIA, or
stroke (includes both minor and major strokes) within 60
days before the CAS procedure. All documented complica-
tions that occurred periprocedurally and postprocedurally
(within 30 days) were noted and recorded. The procedural
and 30-day events are not differentiated in the statistical
analysis due to the small sample size of each event category
and will be referred to as combined peri-/postprocedural.
Statistical analyses considered the following outcomes:
myocardial infarction (MI), TIA, stroke, death, as well as
combined adverse events (AEs), which included patients
with any of the aforementioned complications.
Several stent systems and DPF types can be used,
depending on physician preference, institutional availability,and trial protocol, becausemany of the procedures were part
of a prospective clinical trial (Table II). The stent types
included Acculink (Abbott Vascular, Santa Clara, Calif),
Precise (Cordis Endovascular, Miami Lakes, Fla), Wallstent
(Boston Scientiﬁc, Natick, Mass), Xact (Abbott Vascular),
Protégé (ev3 Endovascular Inc, Plymouth,Minn), andNex-
stent (EndoTex Interventional Systems, Cupertino, Calif).
The ﬁlter types included Accunet (Abbott Vascular),
Angioguard (Cordis Endovascular), FilterWire (Boston
Scientiﬁc), Emboshield (Abbott Vascular), Spider (ev3
Endovascular Inc), and Fibernet (Lumen Biomedical Inc,
Maple Grove, Minn). Patients who received proximal and
distal occlusion devices, such as ﬂow reversal devices, were
excluded from the study.
Filter design characteristics. The DPF design charac-
teristics were measured in previous studies conducted in our
laboratory in an in vitro setting (Fig).15-19The characteristics
are summarized in Table III and deﬁned as follows.
Capture efﬁciency was measured using a ﬂow apparatus
with ﬁve milligrams of dyed 200-mm nominal diameter poly-
mer microspheres (larger than the pore size of the devices,
except Spider RX, which was tested with 300-mm-diameter
particles) injected into the blood mimicking ﬂuid, simulating
potential plaque embolization. The ideal value is 100%.17
Capture efﬁciency was calculated based on a particle suspen-
sion injected into a carotid artery bifurcation model and the
number of particlesmissedby theDPF as seen in the following
equation16:
Capture efficiency
¼ 100 ð½particles missed by DPFO½total particles
 particles in external carotid artery
 particles left in syringeÞ  100:
Vascular resistance is deﬁned as the ratio of pressure
gradient across the DPF to the ﬂow rate in the bench-
top apparatus.17 The resistance to the ﬂow was calculated
as the ratio of the time-varying pressure gradient across
the DPF to the time-varying ﬂow rate in the internal
carotid artery as seen in the following equation16:
R ¼ ðPCCA  PICAÞ=QICA.
Table I. Patient and procedural characteristics
Characteristic
N (%),
n ¼ 729
TIA,
n ¼ 19 (2.6%)
P value
OR (95% CI)
CVA,
n ¼ 38 (5.2%)
P value
OR (95% CI)
Death,
n ¼ 19 (3.6%)
P value
OR (95% CI)
Adverse event,
n ¼ 61 (8.3%)
P value
OR (95% CI)
Age $80 years 141 (19.3) .15 .05 .04 .12
.2 (.03-1.8) 2.0 (1.0-4.1) 2.7 (1.0-7.2) 1.6 (.9-3.0)
Male 465 (63.8) .05 .03 .45 .02
.4 (.2-1.0) .5 (.2-.9) 1.5 (.5-4.2) .5 (.3-.9)
Diabetes mellitus 246 (33.7) .08 .26 .64 .14
2.2 (.9-5.5) 1.4 (.7-2.8) 1.2 (.5-3.3) 1.5 (.9-2.6)
History of hyperlipidemia 527 (72.3) .51 .20 .59 .42
1.4 (.5-4.4) .6 (.3-1.3) .8 (.3-2.0) .8 (.4-1.4)
History of hypertension 633 (86.8) .32 .62 .66 .76
2.8 (.4-21.1) .8 (.3-1.9) .7 (.2-2.6) 1.1 (.5-2.6)
Current smoker 162 (22.2) .90 .31 .99 .35
.9 (.3-2.8) 1.4 (.7-3.0) 1.0 (.3-3.1) 1.3 (.7-2.4)
Atrial ﬁbrillation 117 (16.0) .97 .68 .47 .84
1.0 (.3-3.4) 1.2 (.5-2.8) 1.5 (.5-4.6) 1.1 (.5-2.2)
Prior CEA 311 (42.7) .20 .59 .36 .82
1.4 (.8-2.5) .9 (.5-1.4) .7 (.3-1.5) .9 (.6-1.4)
Restenosis post CEA 179 (24.5) .87 .13 .23 .31
1.1 (.4-2.8) .5 (.2-1.2) .4 (.1-1.7) .7 (.4-1.4)
CHF 137 (18.8) .40 .10 .12 .04
1.5 (.5-4.4) 1.8 (.9-3.8) 2.2 (.8-6.0) 1.8 (1.0-3.4)
Prior MI 182 (25.0) .69 .56 .41 .39
.8 (.2-2.4) .8 (.3-1.7) .6 (.2-2.1) .7 (.4-1.4)
Prior CABG 253 (34.7) .21 .03 .26 .03
.5 (.2-1.5) .4 (.2-0.9) .5 (.2-1.6) .5 (.3-.9)
Prior TIA 223 (30.6) .04 .05 .44 .02
2.6 (1.0-6.5) 1.9 (1.0-3.7) 1.5 (.6-3.8) 1.9 (1.1-3.2)
Prior CVA 236 (32.4) .13 <.0001 .04 .02
.4 (.1-1.3) 4.2 (2.1-8.1) 2.6 (1.0-6.5) 1.8 (1.1-3.1)
PVD 216 (29.6) .41 .92 .86 .46
.6 (.2-1.9) 1.0 (.5-2.0) .9 (.3-2.6) .8 (.4-1.4)
CAD 479 (65.7) .23 .73 .68 .61
.6 (.2-1.4) .9 (.4-1.7) .8 (.3-2.1) .9 (.5-1.5)
ESRD 23 (3.2) .60 .45 .07 .12
1.7 (.2-13.6) 1.8 (.4-7.8) 4.1 (.9-19.0) 2.5 (.8-7.6)
COPD 147 (20.2) .92 .78 .71 .76
1.1 (.3-3.2) .9 (.4-2.1) .8 (.2-2.7) .9 (.4-1.8)
Contralateral occlusion 129 (17.7) .70 .45 .61 .87
1.2 (.4-3.8) .7 (.3-1.8) 1.3 (.4-4.1) .9 (.5-1.9)
Asymptomatic 430 (59.0) .57 .0003 .0038 .0002
.8 (.3-1.9) .3 (.1-.5) .2 (.06-.6) .3 (.2-.6)
Close cell stent 131 (18.0) .28 .07 .88 .06
1.8 (.6-5.1) 1.9 (.9-4.1) .9 (.3-3.2) 1.8 (1.0-3.3)
CABG, Coronary artery bypass graft; CAD, coronary artery disease; CEA, carotid endarterectomy; CHF, congestive heart failure; CI, conﬁdence interval;
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident (stroke); ESRD, end-stage renal disease; MI, myocardial infarction; OR, odds
ratio; PVD, peripheral vascular disease; TIA, transient ischemic attack.
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total surface area.
Pore density is the ratio of total number of pores to total
surface area. Porosity, pore density, and number of pores
were calculated from confocal microscopic images of the
ﬁlters removed from the guidewire and mounted ﬂat on
the microscope slide with deionized water.19
Eccentricity refers to whether or not the DPF design
is concentric and can be categorized by viewing the
symmetry of the DPF basket inlet.
Wall apposition refers to a gap between the DPF and
the arterial wall and is expressed as a percentage of vesselcross-sectional area at the site of device deployment. This
value was quantiﬁed using photographs of the DPF in
the coronal plane. The ideal value is 0%, or no gap.18
Wall apposition was measured by taking photographs of
the DPF deployed in a 5.5-mm inner diameter silicone
tube18; gaps between the DPF and the vessel wall were
colored red and the ratio of the red area to the tube
cross-sectional area was subsequently calculated.
The ﬁlter usage distribution is given in Table IV.
Statistical analysis. Peri-/postprocedural outcome
complications, patient characteristics (Table I), ﬁlter type
(Tables II and IV), and ﬁlter characteristics (Tables III and
Table III. DPF design characteristics
DPF Accunet, n ¼ 429 Angioguard, n ¼ 114 FilterWire, n ¼ 113 Spider, n ¼ 45 Emboshield, n ¼ 24
Capture efﬁciency 95.1 63.7 96.1 99.9 64.6
Vascular resistance 24.8 30.6 12.8 3.5 14.7
Porosity 4.5 11.3 12.9 50.4 2.2
No. of pores 912 1100 2576 1563 400
Pore density 4.4 14.4 13.6 10 1.4
Wall apposition .075 4.2 .65 .49 0
Concentric 1 1 0 0 1
Capture efﬁciency, Percentage of emboli captured by DPF; DPF, distal protection ﬁlter; Pore density, ratio of total number of pores to total surface area DPF
basket; Porosity, percentage of porous surface area to total surface area of DPF basket; Vascular resistance, expressed as a ratio of the vascular resistance in the
internal carotid artery at full ﬁlter conditions normalized to the initial conditions;Wall apposition, represented by a gap between the device and the arterial wall
and expressed as a percentage of the vessel cross-sectional area at the site of device deployment.
Table II. Distal protection ﬁlter used in the carotid artery stenting procedures
Filter name N (%), n ¼ 729
TIA
P value
OR (95% CI)
CVA
P value
OR (95% CI)
Death
P value
OR (95% CI)
Adverse event
P value
OR (95% CI)
Accunet 429 (58.8) .02 .03 .03 .0007
.3 (.1-.8) .5 (.2-.9) .3 (.1-.9) .4 (.2-.6)
Angioguard 114 (15.6) .06 .98 .44 .30
2.6 (.9-6.9) 1.0 (.4-2.5) 1.5 (.5-4.8) 1.4 (.7-2.7)
FilterWire 113 (15.5) .19 .16 .60 .07
2.0 (.7-5.6) 1.7 (.8-3.8) .7 (.1-3.0) 1.8 (.9-3.4)
Spider 45 (6.17) .43 .26 <.0001 .02
1.8 (.4-8.1) 1.8 (.6-5.5) 8.6 (3.1-24.2) 2.7 (1.2-6.1)
Emboshield 24 (3.3) n/a .81 n/a .48
.8 (.1-5.9) .5 (.06-3.6)
Fibernet 4 (.5) n/a .003 n/a .01
19.1 (2.6-139.8) 11.7 (1.6-84.7)
Accunet (baseline for below analysis) 429 (58.8) n/a n/a n/a n/a
Angioguard 114 (15.6) n/a .21 .94 .59
1.4 (.5-3.7) n/a 2.2 (1.04-4.5)
FilterWire 113 (15.5) n/a .79 .96 .98
2.2 (1.0-5.2) n/a 2.6 (1.3-5.3)
Spider 45 (6.17) n/a .97 .92 .31
2.5 (.8-7.9) n/a 4 (1.7-9.6)
Emboshield 24 (3.3) n/a .36 .95 .17
1.1 (.1-8.8) n/a .8 (.1-6.2)
Fibernet 4 (.5) n/a n/a n/a n/a
CI, Conﬁdence interval; CVA, cerebrovascular accident (stroke); n/a, not available; OR, odds ratio; TIA, transient ischemic attack.
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was performed using SAS version 9.2 (SAS Institute, Cary,
NC) to determine correlations between patient character-
istics, ﬁlter type, and procedure outcome. Univariate
analysis with a signiﬁcance level of P # .05 compared the
binary recorded clinical variables to each potential outcome
as well as to a composite AE outcome. The P value, odds
ratio (OR), and 95% conﬁdence interval (CI) were recor-
ded for each variable and are given in Tables I and II. Note
that OR >1 corresponds to an increased likelihood of
AE occurrence, and, conversely, OR <1 corresponds to
a decreased likelihood of AE occurrence. The signiﬁcant
variables identiﬁed in the univariate analysis were then used
for multivariate analysis as well as those identiﬁed by the
backward elimination method using SAS. A signiﬁcance
level of P # .05 was used, which correlated with a Waldc2 $ 2, determined if a variable was suitable for inclusion
in the multivariate analysis. The Hosmer-Lemeshow
goodness-of-ﬁt test was used to identify good-ﬁt models,
where P # .05 represented an ill-ﬁt model; all models with
P > .05 were identiﬁed as good-ﬁt models.20 Because
nearly 60% of the patient population used the Accunet
ﬁlter, we performed two different statistical analyses to
accommodate for the skewed nature of the ﬁlter distribu-
tion. The initial statistical analysis was conducted with all
ﬁve ﬁlters being compared with the average. The second
analysis used Accunet as the baseline performance with the
remaining four ﬁlters compared against this new baseline.
RESULTS
A total of 1150 CAS records were reviewed, of which
713 patients and 731 procedures met the inclusion criteria,
Table IV. DPF distribution
DPF N (%), n ¼ 729 TIA (%), n ¼ 729 CVA (%), n ¼ 729 Death (%), n ¼ 729 Adverse event (%), n ¼ 729
Accunet 429 (58.8) 6 (.008) 16 (.02) 6 (.008) 23 (.03)
Angioguard 114 (15.6) 6 (.008) 6 (.008) 4 (.005) 12 (.02)
FilterWire 113 (15.5) 5 (.007) 9 (.01) 2 (.003) 14 (.02)
Spider 45 (6.2) 2 (.003) 4 (.005) 6 (.008) 8 (.01)
Emboshield 24 (3.3) 0 1 (.001) 1 (.001) 2 (.003)
Fibernet 4 (.6) 0 2 (.003) 0 2 (.003)
CVA, Cerebrovascular accident (stroke); DPF, distal protection ﬁlter; TIA, transient ischemic attack.
Table V. DPF design characteristics and statistical signiﬁcance.
Design characteristic, n ¼ 725
TIA
P value
Coefﬁcient
CVA
P value
Coefﬁcient
Death
P value
Coefﬁcient
Adverse event
P value
Coefﬁcient
Capture efﬁciency .20 .92 .93 .65
.0006 .0001 0 .0004
Vascular resistance .56 .08 .007 .01
.0005 .002 .002 .003
Porosity .11 .08 <.0001 .0007
.0009 .001 .002 .003
No. of pores .07 .05 .35 .006
.0005 .0004 .0003 .0005
Pore density .004 .09 .08 .001
.004 .003 .002 .007
Wall apposition .03 .63 .29 .10
.009 .003 .004 .01
Concentric .11 .04 .02 .02
.76 .75 1.09 .90
OR (95% CI) .5 (.2-1.2) .5 (.2-.9) .3 (.1-.9) .4 (.2-.7)
Capture efﬁciency, Percentage of emboli captured by DPF; CI, conﬁdence interval; CVA, cerebrovascular accident (stroke); DPF, distal protection ﬁlter; OR,
odds ratio; Pore density, ratio of total number of pores to total surface area DPF basket; Porosity, percentage of porous surface area to total surface area of DPF
basket; TIA, transient ischemic attack; Vascular resistance, expressed as a ratio of the vascular resistance in the internal carotid artery at full ﬁlter conditions
normalized to the initial conditions; Wall apposition, represented by a gap between the device and the arterial wall and expressed as a percentage of the vessel
cross-sectional area at the site of device deployment.
A total of 725 patients were used in this analysis because Fibernet does not have quantiﬁed ﬁlter characteristics.
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that were both included in the study. The 30-day follow-
up for 38% of the records reviewed was performed at
regional hospitals and not at the center that performed
the CAS intervention. Of the 731 records, there were 19
TIAs (2.6%), 38 strokes (5.2%), one MI (0.1%), 19 deaths
(3.6%), and a total of 61 patients with AEs (8.3%). Due to
the single MI complication, this record was excluded from
the analysis. One death was due to non-neurologic compli-
cations and was also excluded from the analysis. The
remaining 729 procedures had similar statistics, with 19
TIAs (2.6%), 38 strokes (5.2%), 18 deaths (2.5%), and 59
total complications (8.1%). The average age was 71 6 9
years, with 141 octogenarians (19.3%). Nearly two thirds
(n ¼ 465 [63.8%]) were male, and a similar fraction were
asymptomatic (n ¼ 430 [59%]). The stroke and death rates
for asymptomatic patients were 2.5% (n ¼ 11 events per
430 patients) and 1% (n ¼ 4 events per 430 patients),
respectively. Conversely, the stroke and death rates for
symptomatic patients were 9% (n ¼ 27 events per 299
patients) and 4.7% (n ¼ 14 events per 299 patients),respectively. Considering the composite of all AEs, these
were 4.9% (n ¼ 21 events per 430 patients) and 12.7%
(n ¼ 38 events per 299 patients) for asymptomatic and
symptomatic patients, respectively.
Six different DPFs were used in the 729 procedures:
Accunet (n ¼ 429 [58.8%]), Angioguard (n ¼ 114
[15.6%]), FilterWire (n ¼ 113 [15.5%]), Spider (n ¼ 45
[6.2%]), Emboshield (n ¼ 24 [3.3%]), and Fibernet (n ¼
4 [0.5%]). Complete DPF distribution and associated
procedural complications are given in Table IV. Due to
the low number of patients treated with Fibernet, it was
excluded from the ﬁlter analysis but was included in the
clinical outcome analysis.
Univariate analysis. Several variables were found to
be signiﬁcant, as detailed in Tables I and II for the P
value, OR, and CI of each variable and ﬁlter type, when
compared with the response variables (peri/postprocedural
complications). For the composite of AEs, gender (male;
P ¼ .02; OR, 0.5), congestive heart failure (CHF; P ¼ .04;
OR, 1.8), prior coronary artery bypass graft (CABG; P¼ .03;
OR, 0.5), prior TIA (P ¼ .02; OR, 1.9), prior CVA
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.0002; OR, 0.3) were all found to be signiﬁcant. Peri-/
postprocedural death was associated with age (age $80
years; P ¼ .04; OR, 2.7), prior CVA (P ¼ .04; OR, 2.6),
and asymptomatic (P ¼ .0038; OR, 0.2). Peri-/post-
procedural stroke was associated with age (age $80 years;
P ¼ .05; OR, 2.0), gender (male; P ¼ .03; OR, 0.5), prior
CABG (P ¼ .03; OR, 0.4), prior TIA (P ¼ .05; OR, 1.9),
and especially prior stroke (P # .0001; OR, 4.2) as well as
asymptomatic (P ¼ .0003; OR, 0.3). Peri-/postprocedural
TIA was associated with gender (male; P ¼ .05; OR, 0.4)
and prior TIA (P ¼ .04; OR, 2.6).
The univariate analysis for ﬁlter design type yielded
signiﬁcant variables when considering the average of the
ﬁlter results to be the baseline, whereas no signiﬁcance was
established when the Accunet results were used as the base-
line (being the majority of the ﬁlter demographics at nearly
60%). The DPF design characteristics revealed several signif-
icant results (Table V). The composite of AE was negatively
associated with both vascular resistance (P¼ .01) and eccen-
tricity (P ¼ .02) and positively associated with porosity
(P ¼ .0007), number of pores (P ¼ .005), and pore density
(P¼ .001). Peri-/postprocedural death was negatively asso-
ciated with both vascular resistance (P ¼ .007) and eccen-
tricity (P ¼ .02) and positively with porosity (P < .0001).
Peri-/postprocedural stroke was positively associated with
number of pores (P ¼ .05) and negatively associated with
eccentricity (P ¼ .04). Peri-/postprocedural TIA was posi-
tively associated with both pore density (P ¼ .004) and wall
apposition (P ¼ .03).
Subgroup analysis. The outcome of the subgroup
analysis is included in Tables VI and VII (online only)
with several signiﬁcant groups identiﬁed. Table VI (online
only) shows the results for symptomatic vs asymptomatic
patients with each patient characteristic. It also identiﬁes
correlations with each of the four response variables (TIA,
stroke, death, and AE). Notable signiﬁcance was seen for
the following categories: (1) Symptomatic patients with
a history of CHF have a higher risk of AE (P ¼ .0015; OR,
3.3), peri-/postprocedural stroke (P ¼ .008; OR, 3.1), and
peri-/postprocedural TIA (P ¼ .05; OR, 3.9). (2) Symp-
tomatic patients who underwent CAS with a closed cell
stent (Nexstent, Endotex, Wallstent, and Xact, but not
Precise, Smart, Cordis, or Acculink) have a higher risk of
AE (P ¼ .02; OR, 2.5) and peri-/postprocedural stroke
(P ¼ .05; OR, 2.4). (3) Symptomatic patients with
a history of stroke were at higher risk for peri-/post-
procedural stroke (P ¼ .002; OR, 4.4). (4) Asymptomatic
octogenarian patients (P ¼ .02; OR, 4.3) as well as those
with a history of TIA (P ¼ .05; OR, 3.5) both had higher
risk of peri-/postprocedural stroke.
Similarly, Table VII (online only) shows the outcome
of the subgroup analysis for octogenarians vs nonoctoge-
narians as compared with each patient characteristic and
identiﬁes correlations with each of the four response vari-
ables. Notable signiﬁcance was seen for the following cate-
gories. (1) Nonoctogenarians with a history of stroke had
a greater risk of peri-/postprocedural stroke (P ¼ .0001;OR, 5.2), whereas those who were asymptomatic had
signiﬁcantly lower risk (P ¼ .0003; OR, 0.2). (2) Male
octogenarian patients had a lower risk (P ¼ .02; OR,
0.2) of peri-/postprocedural stroke. (3) Nonoctogenarians
with a history of CHF (P ¼ .02; OR, 4.3) and stroke (P ¼
.03; OR, 3.9) had greater risk of peri-/postprocedural
death, whereas those who were asymptomatic had a lower
risk of death (P ¼ .01; OR, 0.1). (4) Octogenarians with
a previous CABG procedure had lower risk of an AE
(P ¼ .05; OR, 0.2). (5) Nonoctogenarians with a history
of CHF had a higher risk of a peri-/postprocedural compli-
cation (P ¼ .02; OR, 2.3), and those who were asymptom-
atic had a lower risk (P ¼ .0016; OR, 0.3).
Multivariate analysis. The Hosmer-Lemeshow good-
ness-of-ﬁt test revealed models for the response variables
AE, death, and stroke to be good-ﬁt models (P $ .05) in
multivariate analysis.
Adverse events. Being male, asymptomatic, and use of
a closed cell stent all had OR <1, signiﬁcant univariate P
values, and a combined model P value of .57. Having
a history of CHF, stroke, and TIA (each with OR >1)
led to a model P value of .72.
Peri-/postprocedural stroke. Asymptomatic male
patients (both OR <1) had a model P value of .70. Octo-
genarian patients with a history of TIA and stroke (all OR
>1) had a model P value of .97.
Peri-/postprocedural death. Octogenarians with
a history of stroke (bothOR>1) had amodel P value of .62.
Multivariate analysis did not identify any signiﬁcant
DPF design characteristics but did reveal that the afore-
mentioned clinical variables remained signiﬁcant.
DISCUSSION
The purpose of this single-arm, multicenter study was
to review retrospectively CAS procedures to ﬁnd correla-
tions between peri-/postprocedural complications, clinical
variables, ﬁlter type, and ﬁlter characteristics determined
by in vitro testing. The use of CAS for asymptomatic
patients currently is not approved by Centers for Medicare
& Medicaid Services. In our study, these patients were
treated under the auspices of a trial or after they had
received approval from non-Centers for Medicare &
Medicaid Services payers. The outcome of this study can
help provide additional information regarding ﬁlter choice
to clinicians when evaluating patients potentially suitable
for CAS. Of the seven DPF characteristics considered in
this study, vascular resistance, eccentricity, and capture efﬁ-
ciency had a negative correlation with AE, whereas
porosity, wall apposition, and pore density had positive
correlations. Vascular resistance, porosity, pore density,
and eccentricity were found to be signiﬁcant with P <
.05 (Table V). Similarly, vascular resistance and eccentricity
had negative correlations with peri-/postprocedural death,
whereas porosity had a positive correlation. The following
ﬁlter design characteristics were independently signiﬁcant
for minimizing peri-/postprocedural AEs: higher vascular
resistance, concentric in shape, greater capture efﬁciency,
lower porosity, lower number of pores, and lower pore
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also found to be independently signiﬁcant for minimization
of peri-/postprocedural TIAs. Because multivariate analysis
was unable to identify any signiﬁcant DPF design charac-
teristics, we cannot deﬁnitively conclude that certain ﬁlters
are safer to use than others. However, utilizing the univar-
iate results, it appears that the Accunet, Angioguard, and
Emboshield ﬁlters have a favorable design as it relates to
the minimization of AEs (Table III).
As previously reported in the literature by Schlüter
et al,14 Voeks et al,21 Roubin et al,22 and Kastrup et al,23
octogenarians had an increased risk of postprocedural stroke
and death, which was consistent with our results (Table I).
Interestingly, gender was seen to favor males as having lower
risk of peri-/postprocedural TIA, stroke, and AE compared
with females. This ﬁnding did not agree with the results of
Schlüter et al,14 who found males to be at higher risk than
females. Their study also showed an increased risk for
patients with diabetes mellitus, whereas no signiﬁcance was
found in our results. Consistent with our ﬁndings, Roubin
et al22 and Qureshi et al24 did not ﬁnd diabetes mellitus to
have any signiﬁcant impact on AEs. In our results, history
of stroke, CHF, and TIA also showed signiﬁcant increase
in peri-/postprocedural complications.
To date, few studies have focused on correlating the
type of DPF used and the 30-day outcome. According to
Shah et al,25 the ideal test would be a comprehensive
comparative randomized trial using multiple types of ﬁlters.
There is a need for both prospective and retrospective
studies to determine if ﬁlter type, and thus ﬁlter design char-
acteristics, correlates with CAS procedural complications.
With the results of the present investigation, physicians
will have more information regarding the ﬁlter of choice
and clinical variables associated with procedural outcome.
Iyer et al26 conducted a study correlating 30-day CAS
outcomes to embolic protection devices (includes DPF and
both proximal and distal balloon occlusion devices). The
study concluded that there were no signiﬁcant differences
in risks of procedural AEs between different devices or
types of devices. Their results showed an increased risk of
30-day AEs with the Accunet ﬁlter compared with Filter-
Wire. As described in Table II, when the average ﬁlter
result is the baseline, Accunet is signiﬁcant for all three
potential complications including TIA (P ¼ .02; OR,
0.3), stroke (P ¼ .03; OR, 0.5), and death (P ¼ .03;
OR, 0.3) as well as for any AE (P ¼ .0007; OR, 0.4). These
results would identify Accunet as the best ﬁlter choice
because it has a small OR (<1), meaning that there is
less chance of complication. The Spider ﬁlter is also seen
as signiﬁcant for both peri-/postprocedural death (P #
.0001; OR, 8.6) and overall AEs (P ¼ .02; OR, 2.7).
One limitation of the study is that this outcome could be
due to the fact that Accunet was the most frequently
used device in the CAS procedures, whereas FilterWire
was the most common in the study by Iyer et al.26 Such
comparison illustrates the importance of having an even
distribution of ﬁlter types regarding correlation of DPF
with CAS outcome.An equally important study was conducted by Rofﬁ
et al,27 who focused on the impact of ﬁlter design on blood
ﬂow impairment in the internal carotid artery among
patients undergoing ﬁlter-protected CAS. They concluded
that there was a positive correlation between the type of
ﬁlter used and the occurrence of ﬂow impairment.27
Contrary to their ﬁndings, our results indicate that vascular
resistance was signiﬁcant for negative correlations with
both peri-/postprocedural death and AEs (Table VII,
online only). Among the DPF design characteristics listed
in Table VII (online only) only capture efﬁciency was
found not signiﬁcantly correlated with any speciﬁc or
comprehensive AE. These results strongly support the
positive correlation between DPF design characteristics
and CAS complications.
The CAS procedural stroke and death rates observed in
our study are higher than the American Heart Association
guidelines for carotid intervention, which are 3% for
asymptomatic patients and 6% for symptomatic patients.
A major contributing factor to this high neurologic AE
rate is that a large fraction of the cohort (40%) was
composed of symptomatic patients. Part of the cohort for
this study were also participating in the SAPPHIRE (Stent-
ing and Angioplasty with Protection in Patients at High
Risk for Endarterectomy), ARCHeR (ACCULINK for
Revascularization of Carotids in High-Risk Patients),
BEACH (Boston Scientiﬁc EPI: A Carotid Stenting Trial
for High Risk Surgical Patients), or CABERNET (Carotid
Artery Revascularization Using the Boston Scientiﬁc EPI
Filterwire EX/EZ and the EndoTex NexStent) trials, all
of which generally include high-risk patients considered
unsuitable for CEA. Currently, both the American Heart
Association 2011 and the UK National Institute for Clin-
ical Excellence 2011 guidelines support the use of CAS
for treatment of standard-surgical-risk patients, whereas
the European Society for Vascular Surgery 2009 guidelines
stress that CAS be restricted to high-surgical-risk patients.
This discrepancy is due in part to the 2009 date for the
European Society for Vascular Surgery decision, which
predates the results of CREST (Carotid Revascularization
Endarterectomy Versus Stenting Trial).7 According to the
most recent study conducted comparing CEA with CAS
procedures, CREST released its ﬁnal results at the end of
2010 and revealed that the primary outcome was similar
between the two procedures, but that there was an age
dependency. To date, CREST is the largest randomized
trial of carotid revascularization,7 and it reports an increase
in procedural CAS complications for octogenarians.21 In
the present work, the subgroup of patients <80 years
with a history of stroke had an increased risk of peri-/post-
procedural stroke or death compared with octogenarians
(Table VI, online only). Conversely, octogenarian males
were at a much greater risk of peri-/postprocedural stroke
(OR, 4.3) compared with younger male patients (OR, 1.2;
Table VI, online only).
Study limitations. One limitation of our study is the
apparently uneven distribution of ﬁlter type used. As seen
from the high number of procedures using the Accunet
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conducted in the following two ways: ﬁrst by comparing
each DPF with the average of all DPFs used in the study,
and second by comparing each DPF to Accunet, which
was set at the baseline. For this reason, the study was not
truly randomized because there are underlying reasons
for choosing ﬁlter type, whether it is institution speciﬁc
or physician speciﬁc. A future study should attempt a
randomized, prospective study with an even distribution
of ﬁlter type used for all CAS patients, albeit a challenging
task to accomplish. Another limitation is that we did not
take into account the experience of the physician or the
frequency of CAS performed at the speciﬁc institutes,
both of which can affect the outcome of the procedure.
It must also be noted that the 30-day follow-up studies
were documented by a combination of independent
neurologists for those patients participating in sponsored
trials and by neurologists at the UPMC and WPAHS
hospital sites for those not participating in trial studies.
CONCLUSIONS
Positive correlations between CAS procedural compli-
cations, clinical variables, and the type of DPF and its
design characteristics can be derived by retrospectively
reviewing procedural information and performing univar-
iate and multivariate analyses. The analysis with Accunet
used as the baseline in comparison with the other four
ﬁlters did not show any statistically signiﬁcant results
when associating ﬁlter type to procedural outcome. The
following ﬁlter design characteristics are independently
signiﬁcant for minimizing peri-/postprocedural adverse
outcomes: higher vascular resistance, concentric in shape,
greater capture efﬁciency, lower porosity, lower number
of pores, and lower pore density. Lower porosity and
smaller wall apposition were also found to be indepen-
dently signiﬁcant for minimization of peri-/postprocedural
transient ischemic attacks. These appealing ﬁlter design
characteristics should be taken into consideration for future
generations of DPFs.
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Table VI (online only). Symptomatic vs asymptomatic patient characteristics
Characteristic,
n ¼ 729
TIA
P value
OR (95% CI)
CVA
P value
OR (95% CI)
Death
P value
OR (95% CI)
Adverse event
P value
OR (95% CI)
Asym Sym Asym Sym Asym Sym Asym Sym
Age $80 years .95 .41 .02 .68 .11 .24 .40 .33
n/a .4 (.05-3.4) 4.3 (1.3-14.5) 1.2 (.5-3.0) 5 (.7-36.1) 1.9 (.6-6.0) 1.6 (.6-4.4) 1.4 (.7-3.1)
Male .36 .07 .07 .19 .65 .53 .12 .07
.6 (.2-1.9) .3 (.07-1.1) .3 (.1-1.1) .6 (.3-1.3) 1.7 (.2-16.5) 1.5 (.4-4.8) .5 (.2-1.2) .5 (.3-1.0)
Diabetes mellitus .11 .41 .58 .06 .67 .36 .45 .15
2.8 (.8-1.2) 1.7 (.5-6.7) .7 (.2-2.6) 2.1 (1.0-4.8) .6 (.1-5.9) 1.6 (.6-4.9) 1.4 (.6-3.4) 1.7 (.8-3.4)
History of
hyperlipidemia
.28 .88 .58 .12 .96 .33 .24 .12
3.1 (.4-24.9) .9 (.2-3.7) 1.5 (.3-7.2) .5 (.2-1.2) n/a .6 (.2-1.7) 2.1 (.6-7.3) .6 (.3-1.1)
History of
hypertension
.70 .96 .22 .92 .54 .76 .51 .44
1.5 (.2-12.1) n/a .4 (.1-1.7) 1.1 (.3-3.7) .5 (.05-4.8) .8 (.2-3.7) .7 (.2-2.1) 1.6 (.5-5.6)
Current smoker .96 .88 .20 .85 .97 .71 .36 .77
1.0 (.2-4.6) .9 (.2-4.3) 2.2 (.6-7.8) 1.1 (.4-2.7) n/a 1.2 (.4-4.1) 1.6 (.6-4.2) 1.1 (.5-2.4)
Atrial ﬁbrillation .65 .70 .58 .49 .97 .27 .47 .5
.6 (.1-5.0) 1.4 (.3-6.8) .5 (.07-4.4) 1.4 (.5-3.7) n/a 2.0 (.6-6.6) .6 (.1-2.5) 1.3 (.6-3.1)
Prior CEA .10 .93 .08 .13 .99 .50 .11 .23
1.7 (.9-3.4) 1.0 (.3-3.2) 1.8 (.9-3.4) .5 (.2-1.2) 1.0 (.3-3.7) .7 (.2-2.1) 1.5 (.9-2.5) .6 (.3-1.3)
Restenosis
post CEA
.99 .70 .66 .11 .85 .37 .74 .30
1.0 (.3-3.5) 1.3 (.3-5.5) 1.3 (.4-3.9) .2 (.03-1.4) .8 (.1-6.7) .4 (.06-2.9) 1.1 (.5-2.7) .6 (.2-1.6)
CHF .45 .05 .39 .008 .15 .28 .54 .0015
.4 (.06-3.6) 3.9 (1.0-15.2) .4 (.05-3.2) 3.1 (1.3-7.3) 4.2 (.6-3.2) 1.9 (.6-6.4) .7 (.2-2.3) 3.3 (1.6-7.0)
Prior MI .51 .76 .62 .62 .38 .29 .92 .65
.6 (.1-2.8) 1.3 (.3-6.3) 1.4 (.4-4.8) .7 (.2-2.3) 2.4 (.3-17.3) .3 (.04-2.6) .9 (.4-2.5) .8 (.3-2.0)
Prior CABG .61 .23 .19 .16 .61 .19 .38 .09
.7 (.2-2.8) .28 (.03-2.2) .4 (.08-1.7) .5 (.2-1.3) 1.7 (.2-12.0) .4 (.1-1.7) .6 (.2-1.7) .5 (.2-1.1)
Prior TIA .63 .06 .05 .56 .97 .79 .23 .81
1.5 (.3-7.1) 7.2 (.9-58.8) 3.5 (1.0-12.3) .8 (.4-1.7) n/a .9 (.3-2.5) 1.9 (.7-5.4) 1.1 (.5-2.1)
Prior CVA .37 .14 .26 .002 .89 .21 .73 .09
.4 (.05-3.1) .3 (.06-1.5) 2.0 (.6-6.7) 4.4 (1.7-11.2) 1.2 (.1-11.0) 2.1 (.7-6.3) .8 (.3-2.5) 1.8 (.9-3.7)
PVD .49 .64 .26 .41 .39 .52 .41 .13
.6 (.1-2.7) .69 (.1-3.4) 2.0 (.6-6.6) .7 (.3-1.7) 2.3 (.3-16.9) .6 (.2-2.4) 1.6 (.6-3.6) .5 (.2-1.2)
CAD .96 .13 .88 .93 .85 .91 .57 .66
1.0 (.2-3.8) .3 (.08-1.4) 1.1 (.3-4.2) 1.0 (.5-2.3) 1.2 (.1-12.1) .9 (.3-2.8) 1.3 (.5-3.7) .8 (.4-1.7)
ESRD .25 .98 .98 .18 .05 .37 .12 .39
3.5 (.4-29.5) n/a n/a 3.0 (.6-15.4) 1.6 (1-108.8) 2.7 (.3-22.9) 3.5 (.7-16.7) 2.0 (.4-1.1)
COPD .43 .32 .37 .77 .97 .90 .22 .55
.4 (.05-3.4) 2.0 (.5-8.4) .4 (.05-3.1) 1.1 (.4-3.0) n/a 1.1 (.3-4.0) .4 (.1-1.7) 1.3 (.6-2.9)
Contralateral
occlusion
.57 .28 .50 .56 .66 .82 .37 .74
.5 (.1-4.4) 2.2 (.5-9.0) .5 (.06-3.9) .7 (.2-2.2) 1.7 (.2-16.2) 1.2 (.3-4.3) .5 (.1-2.2) 1.1 (.5-2.7)
Closed cell stent .39 .49 .50 .05 .97 .58 .59 .02
1.8 (.5-7.2) .18 (.3-9.0) 1.6 (.4-6.1) 2.4 (1.0-5.9) n/a 1.4 (.4-5.4) 1.3 (.5-3.7) 2.5 (1.1-5.4)
Asym, Asymptomatic; CABG, coronary artery bypass graft; CAD, coronary artery disease; CEA, carotid endarterectomy; CHF, congestive heart failure; CI,
conﬁdence interval; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident (stroke); ESRD, end-stage renal disease; MI, myocardial
infarction; n/a, not applicable (patient did not have characteristic and outcome in question); OR, odds ratio; PVD, peripheral vascular disease; Sym, symp-
tomatic; TIA, transient ischemic attack.
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Table VII (online only). Octogenarian vs nonoctogenarian patient characteristics
Characteristic,
n ¼ 729
TIA
P value
OR (95% CI)
CVA
P value
OR (95% CI)
Death
P value
OR (95% CI)
Adverse event
P value
OR (95% CI)
Age $80
years
Age <80
years
Age $80
years
Age <80
years
Age $80
years
Age <80
years
Age $80
years
Age <80
years
Male .95 .10 .02 .30 .73 .52 .06 .09
n/a .5 (.2-1.2) .2 (.1-.8) .7 (.3-1.4) 1.3 (.2-7.2) 1.5 (.4-5.9) .4 (.1-1.0) .6 (.3-1.1)
Diabetes mellitus .96 .08 .21 .46 .88 .49 .63 .12
n/a 2.3 (.9-6.0) 2.2 (.6-7.3) 1.3 (.6-3.0) 1.1 (.2-6.1) 1.5 (.4-5.0) 1.3 (.4-4.1) 1.6 (.9-3.1)
History of
hyperlipidemia
.95 .65 .66 .08 .36 .18 .61 .23
n/a 1.3 (.4-4.0) 1.3 (.3-5.2) .5 (.2-1.1) 2.7 (.3-23.5) .4 (.1-1.4) 1.4 (.4-4.5) .7 (.3-1.3)
History of
hypertension
.97 .36 .27 .83 .28 .70 .58 .46
n/a 2.6 (.3-19.6) .4 (.1-1.8) 1.1 (.3-3.9) .4 (.07-2.1) 1.5 (.2-11.8) .7 (.2-2.6) 1.5 (.5-4.3)
Current smoker .98 .72 .86 .14 .97 .43 .90 .16
n/a .8 (.3-2.5) 1.2 (.1-1.5) 1.8 (.8-4.2) n/a 1.6 (.5-5.7) .9 (.1-7.3) 1.6 (.8-3.0)
Atrial ﬁbrillation .95 .64 .69 .95 .67 .26 .64 .85
n/a .7 (.2-3.1) 1.3 (.3-5.2) 1.0 (.3-3.1) .6 (.1-5.4) 2.2 (.6-8.3) 1.3 (.4-4.5) .9 (.4-2.2)
Prior CEA .95 .18 .75 .48 .14 .94 .93 .82
n/a 1.5 (.8-2.6) 1.1 (.5-2.8) .8 (.4-1.5) 2.0 (.8-5.2) n/a 1.0 (.5-2.4) .95 (.6-1.5)
Restenosis
post CEA
.96 .84 .74 .14 .61 .96 .85 .33
n/a 1.1 (.4-2.8) .8 (.2-3.5) .4 (.1-1.3) 1.5 (.3-7.4) n/a .9 (.2-3.2) .7 (.3-1.5)
CHF .96 .21 .60 .17 .45 .02 .85 .02
n/a 1.9 (.7-5.6) 1.4 (.4-4.9) 1.9 (.8-4.6) .4 (.05-3.7) 4.3 (1.3-14.3) .9 (.3-3.0) 2.3 (1.2-4.6)
Prior MI .95 .97 .91 .37 .27 .72 .39 .51
n/a 1.0 (.3-3.0) .9 (.3-3.3) .6 (.2-1.8) .3 (.04-3.5) .7 (.2-3.5) .6 (.2-2.0) .8 (.3-1.7)
Prior CABG .95 .28 .15 .11 .23 .63 .05 .22
n/a .5 (.2-1.7) .3 (.1-1.5) .4 (.2-1.2) .3 (.03-2.3) .7 (.2-2.7) .2 (.05-1.0) .6 (.3-1.3)
Prior TIA .95 .06 .64 .06 .70 .25 .46 .03
n/a 2.5 (1.0-6.3) 1.3 (.4-4.4) 2.1 (1.0-4.7) .7 (.1-3.8) 2.0 (.6-6.7) 1.4 (.5-4.3) 2.0 (1.1-3.8)
Prior CVA .95 .17 .08 .0001 .64 .03 .18 .07
n/a .4 (.1-1.5) 2.9 (.9-9.7) 5.2 (2.2-12.3) 1.4 (.3-6.7) 3.9 (1.1-13.3) 2.0 (.7-5.8) 1.8 (1.0-3.3)
PVD .95 .40 .60 .71 .59 .71 .31 .87
n/a .6 (.2-1.9) .7 (.1-3.2) 1.2 (.5-2.7) .5 (.06-4.8) 1.3 (.4-4.4) .4 (.1-2.1) 1.0 (.5-1.9)
CAD .95 .23 .50 .30 .06 .52 .99 .45
n/a .6 (.2-1.4) 1.7 (.4-8.2) .7 (.3-1.4) .2 (.04-1.1) 1.5 (.4-5.9) 1.0 (.3-3.3) .8 (.4-1.5)
ESRD .99 .58 .99 .20 .98 .01 .98 .03
n/a 1.8 (.2-14.3) n/a 2.7 (.6-12.2) n/a 7.3 (1.5-36.5) n/a 3.6 (1.1-11.4)
COPD .96 .64 .44 .80 .96 .61 .66 .98
n/a .7 (.2-2.6) .4 (.05-3.6) 1.1 (.4-2.8) n/a 1.4 (.4-5.4) .7 (.1-3.3) 1.0 (.5-2.1)
Contralateral
occlusion
.96 .62 .97 .39 .41 .98 .84 .78
n/a 1.3 (.4-4.1) 1.0 (.2-4.7) .6 (.2-2.0) 2.0 (.4-11.1) 1.0 (.2-4.8) 1.1 (.3-4.4) .9 (.4-2.1)
Asymptomatic .95 .65 .47 .0003 .22 .01 .09 .0016
n/a .8 (.3-2.1) .6 (.2-2.1) .2 (.07-.5) .3 (.07-1.9) .1 (.03-.6) .4 (.1-1.2) .3 (.2-.7)
Closed cell stent .96 .57 .13 .24 .96 .44 .12 .20
n/a 1.4 (.4-4.3) 2.7 (.7-9.9) 1.7 (.7-4.2) n/a 1.7 (.4-6.5) 2.6 (.8-8.1) 1.6 (.8-3.3)
CABG, Coronary artery bypass graft; CAD, coronary artery disease; CEA, carotid endarterectomy; CHF, congestive heart failure; CI, conﬁdence interval;
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident (stroke); ESRD, end-stage renal disease; MI, myocardial infarction; n/a, not
applicable (patient did not have characteristic and outcome in question); OR, odds ratio; PVD, peripheral vascular disease; TIA, transient ischemic attack.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 2 Loghmanpour et al 317.e2
